These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The effect of diltiazem on the disposition of encainide and its active metabolites. Kazierad DJ; Lalonde RL; Hoon TJ; Mirvis DM; Bottorff MB Clin Pharmacol Ther; 1989 Dec; 46(6):668-73. PubMed ID: 2513160 [TBL] [Abstract][Full Text] [Related]
9. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide. Harrison DC; Kates RE; Quart BD Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622 [TBL] [Abstract][Full Text] [Related]
10. Encainide disposition in patients with chronic cirrhosis. Bergstrand RH; Wang T; Roden DM; Avant GR; Sutton WW; Siddoway LA; Wolfenden H; Woosley RL; Wilkinson GR; Wood AJ Clin Pharmacol Ther; 1986 Aug; 40(2):148-54. PubMed ID: 3089668 [TBL] [Abstract][Full Text] [Related]
11. Encainide disposition in patients with renal failure. Bergstrand RH; Wang T; Roden DM; Stone WJ; Wolfenden HT; Woosley RL; Wilkinson GR; Wood AJ Clin Pharmacol Ther; 1986 Jul; 40(1):64-70. PubMed ID: 3087679 [TBL] [Abstract][Full Text] [Related]
12. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808 [TBL] [Abstract][Full Text] [Related]
13. Drug interaction studies and encainide use in renal and hepatic impairment. Quart BD; Gallo DG; Sami MH; Wood AJ Am J Cardiol; 1986 Aug; 58(5):104C-113C. PubMed ID: 2875643 [TBL] [Abstract][Full Text] [Related]
14. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. Funck-Brentano C; Turgeon J; Woosley RL; Roden DM J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of encainide in patients with cirrhosis. Wensing G; Mönig H; Ohnhaus EE; Hoensch HP Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559 [TBL] [Abstract][Full Text] [Related]
16. Comparative antiarrhythmic actions of encainide and its major metabolites. Gomoll AW; Byrne JE; Mayol RF Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755 [TBL] [Abstract][Full Text] [Related]
17. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide. Winkle RA; Peters F; Kates RE; Harrison DC Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150 [TBL] [Abstract][Full Text] [Related]
18. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole]. Thale J; Klein H; Shanks RG; Bender F Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400 [TBL] [Abstract][Full Text] [Related]
20. Metabolite cumulation during long-term oral encainide administration. Kates RE; Harrison DC; Winkle RA Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]